Hemodialysis patients which has Anemia of inflammation Intravenous Ascorbic acid, Intravenous tranexamic acid, Anemia in hemodialysis patients
Conditions
Interventions
20 patients received injections of intravenous ascorbic acid and tranexamic acid during hemodialysis.,20 patients received intravenous ascorbic acid and saline solution during hemodialysis.
Experimental Drug,Experimental Drug
Sponsors
Buriram Hostpital, Thailand
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Kidney failure patients undergoing hemodialysis treatment with hemodialysis who have anemia from inflammatory processes in the body with a hemoglobin level less than or equal to 11 g/dl, a serum ferritin level greater than 800 ng/ml, and a serum transferrin saturation greater than or equal to 40%.
Exclusion criteria
Exclusion criteria: 1) Patients with end stage kidney disease receiving kidney replacement therapy with hemodialysis who have a history of epilepsy. or have had a history of brain surgery 2) Patients with urinary tract stone problems 3) Patients who are allergic to vitamin C injectable form and allergic to tranexamic acid. 4) Patients who have received iron injections within the past 2 months. 5) Patients who refuse to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum iron, Feritin, Total iron binding capacity, Hematocirt 6 months micromol/L, %Tranferin saturation | — |
Secondary
| Measure | Time frame |
|---|---|
| intact Parathyroid hormone, C-reactive protein, Erythrocyte Sedimentation rate, uric acid 6 months pg/ml, mg/L, mm/h, mg/dl(micromol/L) | — |
Countries
Thailand
Contacts
Public ContactTheerapun Boonsayomphu
Buriram Hospital
Outcome results
None listed